Stephenson Cancer Center - Cancer Center Support Grant

史蒂芬森癌症中心 - 癌症中心支持补助金

• 批准号: 10372607
• 负责人: ROBERT S. MANNEL
• 金额: $ 11.5万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10372607
• 关键词: Address; Age; American Indians; Award; COVID-19; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Death Rates; Catchment Area; Categories; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical Research; Clinical Trials Network; Collaborations; Communities; Community Outreach; Development; Diagnosis; Enrollment; Funding; Goals; Health Professional; Health Sciences; Incidence; Institution; Intervention; Investigational Therapies; Journals; Lead; Malignant Neoplasms; Mission; NCI-Designated Cancer Center; National Clinical Trials Network; Nature; Oklahoma; Parents; Patient-Centered Care; Patients; Peer Review; Publications; Publishing; Reporting; Research; Research Personnel; Role; Rural Population; Scientist; Site; Source; Strategic Planning; Training; Training and Education; Translating; Universities; cancer prevention; career; community based research; community engagement; community setting; experience; member; mortality; next generation; novel; treatment trial

Parent Award ABSTRACT The Stephenson Cancer Center (SCC) at the University of Oklahoma continued to grow and mature during its third year of NCI Cancer Center Support Grant (CCSG) funding. As the state's only NCI-Designated Cancer Center, the SCC has a critical mission of eliminating cancer in Oklahoma and beyond through: 1) providing the highest level of research-driven, patient centered care; 2) translating novel discoveries to the clinic and community settings; 3) engaging the community and addressing cancer problems prevalent in the catchment area; and 4) training the next generation of cancer researchers and health professionals. This mission is especially critical in Oklahoma, which has the fourth highest age-adjusted cancer death rate (177.3 per 100,000) among all states (CDC). Efforts to advance this mission are guided by a five-year Strategic Plan (2018-22) and supported by significant institutional commitments on the part of the University and State. The SCC currently has 131 members (71 Full and 60 Associate), representing 32 different academic departments at the OU Health Sciences Center (OUHSC) and OU Norman campuses. These cancer center members published 295 cancer-focused publications in peer reviewed journals. Of these, 22% involved Intra-Programmatic and 9% Inter-Programmatic collaborations. Notably, both of these percentages dipped significantly in 2020, perhaps reflective of obstacles to collaborating in the era of COVID-19. SCC member publications continued to reflect significant collaboration with scientists at other institutions (80%) and, within that category, at other NCI-Designated Cancer Centers (50%). Research at the SCC continues to reflect a strong focus on cancer problems prevalent in Oklahoma, the SCC's catchment area, and especially the state's large American Indian and rural populations that experience significantly higher cancer incidence and mortality rates. The SCC continues to be a national leader in clinical research. During the reporting period, the SCC had 666 accruals to interventional treatment trials and 634 accruals to interventional non- treatment trials. The SCC continues to be the top accruing site in the NCI's National Clinical Trials Network (NCTN), enrolling 288 patients to National Group trials in CY2020. During the reporting period, the SCC was a lead partner in an awarded consortium application (UM1CA186689) for the NCI Experimental Therapeutics Clinical Trials Network (ETCTN), thereby achieving a primary goal in the SCC's 2018-22 Strategic Plan. Activities in the SCC's Education, Training and Career Enhancement (ETCE) Core have grown significantly, highlighted by a continued increase in peer-reviewed training funding (see above). The SCC's Community Outreach and Engagement (COE) Core is continuing to add capacity and take a lead role in promoting and coordinating research focused on the SCC catchment area. The SCC continues to be a premier site nationally for conducting community-based research with tribal partners to address the high cancer incidence and mortality rates among American Indians in the state.

家长奖摘要 俄克拉荷马州大学的斯蒂芬森癌症中心（SCC）继续发展， 在NCI癌症中心支持补助金（CCSG）资助的第三年期间成熟。作为国家的 作为唯一一家NCI指定的癌症中心，SCC的关键使命是在全球范围内消除癌症。 俄克拉荷马州和超越通过：1）提供最高水平的研究驱动，病人 中心护理; 2）将新发现转化为诊所和社区环境; 3）参与 社区和解决在集水区流行的癌症问题;以及4）培训 下一代癌症研究人员和健康专家。这项使命尤其 在俄克拉荷马州，年龄调整后的癌症死亡率排名第四（177.3%）， 10万人）。推进这一使命的努力遵循一项五年期 战略计划（2018 - 22），并得到以下方面的重大机构承诺的支持： 大学和国家。 SCC目前有131名成员（71名正式成员和60名准成员），代表32个不同的 学术部门在健康科学中心（OUHSC）和诺曼 校园。这些癌症中心成员在同行中发表了295篇以癌症为重点的出版物， 审查期刊。其中，22%涉及方案内，9%涉及方案间 合作。值得注意的是，这两个百分比在2020年都大幅下降， 反映了在COVID-19时代合作的障碍。SCC成员出版物 继续反映出与其他机构的科学家的重大合作（80%）， 其他NCI-Designated癌症中心（50%）。SCC的研究仍在继续 为了反映对SCC集水区俄克拉荷马州普遍存在的癌症问题的强烈关注， 特别是该州大量的美洲印第安人和农村人口， 癌症的发病率和死亡率明显较高。 SCC仍然是临床研究的国家领导者。报告期内 SCC有666项应计为干预性治疗试验，634项应计为干预性非治疗试验。 治疗试验SCC仍然是NCI国家临床试验机构中最大的累积站点。 试验网络（NCTN），在CY2020招募288名患者参加国家组试验。期间 在本报告所述期间，SCC是一个中标财团申请的主要合作伙伴 （UM1CA186689）为NCI实验治疗药物临床试验网络（ETCTN）， 从而实现SCC 2018 - 22战略计划中的主要目标。SCC的活动 教育、培训和职业提升（ETCE）核心项目大幅增长， 突出体现在同行审查的培训资金持续增加（见上文）。SCC的 社区外展和参与（COE）核心正在继续增加容量，并采取 在促进和协调以SCC集水区为重点的研究方面发挥主导作用。的scc 继续是一个首要的网站，全国进行以社区为基础的研究与部落 合作伙伴，以解决美国印第安人的高癌症发病率和死亡率， 该州